Novel Gene Therapy Treatment for Head and Neck Cancer with Impressive Phase III Results in China
Sage's very exciting Chinese client, Guangzhou Doublle Bio-Product Co., Ltd., will report the results of its Chinese Phase 3 study of its Adenolysin, a biological for the treatment of late-stage head neck not including nasopharyngeal cancer, by the end of this year. Guangzhou Doublle seeks a development and commercialization partner for global or regional rights to Adenolysin outside China. In the late 1990s as a result of work done by Judah Folkman at the Sydney Farber Insti